PowerShares S&P SmallCap Health Care ETF
Neogen’s Revenue and Income Rose in Fiscal 2Q16
After Neogen’s (NEOG) fiscal 2Q16 earnings report, NEOG rose by 3.9% to close at $60.24 per share in yesterday’s trade.
How Does Cantel Medical Compare to Its Peers?
Cantel Medical outperformed its peers based on the net profit margin, current ratio, PE ratio, and PBV ratio. It outperformed its ETFs based on the PBV ratio.
Cantel Medical’s Revenue and Income Rose in 4Q15
Cantel Medical reported net revenue of $151.255 million in 4Q15—a rise of 6.88% compared to the net revenue of $141.508 million in 3Q15.
How Does Neogen Compare to Its Peers?
The PBV ratios of Neogen (NEOG), Illumina, Bio-Rad Laboratories (ILMN), and VWR International (VWR) are 6.1x, 14.0x, 1.7x, and 2.7x, respectively.
Cantel Medical’s Revenue and Income Rise in Fiscal 1Q16
Cantel Medical (CMN) has a market cap of $2.8 billion. Its YTD (year-to-date) price has been rising quarter-over-quarter in calendar 2015.
Analyzing Neogen’s Performance in 1Q16
Neogen (NEOG) has a market cap of $1.84 billion. The company’s YTD (year-to-date) price movement was stable until the last three months of 2015.